Acimtamig
- Generic Name
- Acimtamig
- Drug Type
- Biotech
- CAS Number
- 2738880-26-5
- Unique Ingredient Identifier
- ND470TT8Y3
- Background
Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Phase 1
Active, not recruiting
- Conditions
- Recurrent Anaplastic Large Cell LymphomaRecurrent Mycosis FungoidesRefractory B-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Anaplastic Large Cell LymphomaRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma
- Interventions
- Biological: Genetically Engineered Lymphocyte Therapy
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04074746
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath